Natixis Advisors LLC Increases Stock Position in Balchem Co. (NASDAQ:BCPC)

Natixis Advisors LLC raised its position in Balchem Co. (NASDAQ:BCPC) by 2.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 21,797 shares of the basic materials company’s stock after buying an additional 453 shares during the period. Natixis Advisors LLC’s holdings in Balchem were worth $3,836,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of BCPC. Victory Capital Management Inc. boosted its holdings in shares of Balchem by 129.7% in the 3rd quarter. Victory Capital Management Inc. now owns 98,853 shares of the basic materials company’s stock worth $17,398,000 after buying an additional 55,822 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Balchem by 32.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 193,146 shares of the basic materials company’s stock valued at $29,929,000 after acquiring an additional 47,036 shares during the last quarter. Congress Asset Management Co. grew its position in shares of Balchem by 12.4% during the 3rd quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company’s stock valued at $53,053,000 after acquiring an additional 33,373 shares during the period. Conestoga Capital Advisors LLC increased its stake in shares of Balchem by 2.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,155,209 shares of the basic materials company’s stock worth $177,844,000 after purchasing an additional 29,825 shares during the last quarter. Finally, Fiera Capital Corp bought a new stake in shares of Balchem in the 3rd quarter worth approximately $4,201,000. Institutional investors own 87.91% of the company’s stock.

Balchem Stock Performance

NASDAQ BCPC opened at $182.44 on Friday. The firm has a market cap of $5.93 billion, a P/E ratio of 49.04, a price-to-earnings-growth ratio of 5.39 and a beta of 0.65. The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21. The company’s 50 day moving average is $173.84 and its 200-day moving average is $166.54. Balchem Co. has a 12-month low of $120.81 and a 12-month high of $186.03.

Analyst Ratings Changes

A number of research firms have issued reports on BCPC. HC Wainwright raised their target price on Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. StockNews.com raised Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.